FindTrial
Sign In

The Effect of Coenzyme Q10 on Endothelial, Vascular and Myocardial Function

The Effect of 6-month Treatment With Coenzyme Q10 on Endothelial, Vascular and Myocardial Function in Patients With Non-alcoholic Fatty Liver Disease

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05941910
Enrollment
60
Registered
2023-07-12
Start date
2023-04-01
Completion date
2023-12-31
Last updated
2023-07-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Alcoholic Fatty Liver Disease

Keywords

Non-alcoholic fatty liver disease, endothelial function, vascular function, myocardial function, coronary flow reserve, endothelial glycocalyx, flow mediated dilation

Brief summary

Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD

Detailed description

Non-alcoholic fatty liver disease (NAFLD) is associated with increased cardiovascular risk. The aim of this study is to investigate the effects of coenzyme Q10 (CoQ10) on endothelial, vascular and myocardial function in patients with NAFLD. In this trial patients with NAFLD will receive 240mg Q10 or placebo. At baseline and at 6 months, will be measured: a) Perfused boundary region (PBR) of the sublingual vessels using the SideviewDarkfieldimaging technique (Microscan, Glycocheck), b) pulse wave velocity (PWV-Complior, ALAM), c) flow-mediated dilation (FMD) of the brachial artery, d) left ventricular (LV) global longitudinal strain (GLS), and e) controlled attenuation parameter (CAP)for the quantification of liver steatosis by liver elastography (Fibroscan, Echosens).

Interventions

DRUGQ10

240mg of Q10 orally, every day

Sponsors

Attikon Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* NAFLD AND one of below : 1. dyslipidemia, as it is defined in the metabolic syndrome 2. increased waist circumference as defined in the metabolic syndrome 3. Arterial hypertension, 4. overweight, (BMI\>25) 5. polycystic ovary syndrome,

Exclusion criteria

* Chronic Kidney Disease * Heart Failure * Liver failure * Pregnancy/ Breast feeding * Active malignancy (receiving Chemotherapy/immunotherapy)

Design outcomes

Primary

MeasureTime frameDescription
The effect of Q10 on Left Ventricular Myocardial FunctionSix monthsThe effect of Q10 on Left Ventricular Global Longitudinal Strain after six month administration of Q10

Countries

Greece

Contacts

Primary ContactVaia Lambadiari, Profesor
vlambad@otenet.gr2105831148

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026